ARTICLE | Company News
Esperion, University of Michigan deal
October 8, 2001 7:00 AM UTC
ESPR obtained an exclusive license from the university to develop paraoxoanse (PON) technology to treat cardiovascular and metabolic diseases. ESPR will pay the university licensing and maintenance fe...